credits bmbl December 7 '06.doc - Central Michigan University

More documents

Recommendations

Info

Agent Summary Statements – Bacterial Agents 5. Centers for Disease Control and Prevention. Suspected cutaneous anthrax in a laboratory worker--Texas, 2002. MMWR Morb Mortal Wkly Rep. 2002;51:279- 81. 6. Centers for Disease Control and Prevention. Human anthrax associated with an epizootic among livestock---North Dakota, 2000. MMWR Morb Mortal Wkly Rep. 2001;50:677-80. 7. Jernigan DB, Raghunathan PS, Bell BP, et al. Investigation of bioterrorismrelated anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis. 2002;8:1019-28. 8. Centers for Disease Control and Prevention. Notice to readers: use of anthrax vaccine in response to terrorism: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2002;51:1024-6. 9. Centers for Disease Control and Prevention. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2000;49(RR15):1-20. 10. Addiss DG, Davis JP, Meade BD, et al. A pertussis outbreak in a Wisconsin nursing home. J Infect Dis. 1991;164:704-10. 11. Christie CD, Glover AM, Willke MJ, et al. Containment of pertussis in the regional pediatric hospital during the greater Cincinnati epidemic of 1993. Infect Control Hosp Epidemiol. 1995;16:556-63. 12. Kurt TL, Yeager AS, Guenette S, et al. Spread of pertussis by hospital staff. JAMA. 1972;221:264-7. 13. Linnemann CC Jr, Ramundo N, Perlstein PH, et al. Use of pertussis vaccine in an epidemic involving hospital staff. Lancet. 1975;2:540-3. 14. Shefer A, Dales L, Nelson M, et al. Use and safety of acellular pertussis vaccine among adult hospital staff during an outbreak of pertussis. J Infect Dis. 1995;171:1053-6. 15. Steketee RW, Wassilak SG, Adkins WN, et al. Evidence for a high attack rate and efficacy of erythromycin prophylaxis in a pertussis outbreak in a facility for the developmentally disabled. J Infect Dis. 1988;157:434-40. 16. Weber DJ, Rutala WA. Management of healthcare workers exposed to pertussis. Infect Control Hosp Epidemiol. 1994;15:411-5. 17. Beall B, Cassiday PK, Sanden GN. Analysis of Bordetella pertussis isolates from an epidemic by pulsed-field gel electrophoresis. J Clin Microbiol. 1995;33:3083- 6. 18. Burstyn DG, Baraff LJ, Peppler MS, et al. Serological response to filamentous hemagglutinin and lymphocytosis-promoting toxin of Bordetella pertussis. Infect Immun. 1983;41:1150-6. 19. Farizo KM, Cochi SL, Zell ER, et al. Epidemiological features of pertussis in the United States, 1980-1989. Clin Infect Dis. 1992;14:708-19. 20. Guris D, Strebel PM, Bardenheier B, et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin Infect Dis. 1999;28:1230-7. 21. Tanaka M, Vitek CR, Pascual FB, et al. Trends in pertussis among infants in the United States, 1980-1999. JAMA. 2003;290:2968-75. 176
Agent Summary Statements – Bacterial Agents 22. Janda WM, Santos E, Stevens J, et al. Unexpected isolation of Bordetella pertussis from a blood culture. J Clin Microbiol. 1994;32:2851-3. 23. Centers for Disease Control and Prevention. Fatal case of unsuspected pertussis diagnosed from a blood culture – Minnesota, 2003. MMWR Morb Mortal Wkly Rep. 2004;53:131-2. 24. Morisset R, Spink WW. Epidemic canine brucellosis due to a new species, Brucella canis. Lancet. 1969;2:1000-2. 25. Spink WW. The nature of brucellosis. Minneapolis: The <strong>University</strong> of Minnesota Press; 1956. 26. Miller CD, Songer JR, Sullivan JF. A twenty-five year review of laboratoryacquired human infections at the National Animal Disease Center. Am Ind Hyg Assoc J. 1987;48:271-5. 27. Olle-Goig J, Canela-Soler JC. An outbreak of Brucella melitensis infection by airborne transmission among laboratory workers. Am J Publ Hlth 1987;77:335-8. 28. Memish ZA, Mah MW. Brucellosis in laboratory workers at a Saudi Arabian hospital. Am J Infect Control. 2001;29:48-52. 29. Grammont-Cupillard M, Berthet-Badetti L, Dellamonica P. Brucellosis from sniffing bacteriological cultures. Lancet. 1996;348:1733-4. 30. Huddleson IF, Munger M. A study of an epidemic of brucellosis due to Brucella melitensis. Am J Public Health. 1940;30:944-54. 31. Staszkiewicz J, Lewis CM, Coville J et al. Outbreak of Brucella melitensis among microbiology laboratory workers in a community hospital. J Clin Microbiol. 1991;29:278-90. 32. Pardon P, Marly J. Resistance of normal or immunized guinea pigs against a subcutaneous challenge of Brucella abortus. Ann Rech Vet. 1978;9:419-25. 33. Mense MG, Borschel RH, Wilhelmsen CL, et al. Pathologic changes associated with brucellosis experimentally induced by aerosol exposure in rhesus macaques (Macaca mulatto). Am J Vet Res. 2004;65:644-52. 34. Madkour MM. Brucellosis: overview. In: Madkour MM, editor. Madkour’s Brucellosis. 2 nd ed. Germany: Berlin Springer Verlag; 2001. 35. Centers for Disease Control and Prevention. Laboratory-acquired human glanders--Maryland, May 2000. MMWR Morb Mortal Wkly Rep. 2000;49:532-5. 36. Glanders. In: Chin J, Ascher M, editors. Control of communicable diseases. Washington, DC: American Public Health Association; 2000. p. 337-8. 37. Howe C, Miller WR. Human glanders: report of six cases. Ann Intern Med. 1947;26:93-115. 38. Srinivasan A, Kraus CN, DeShazer D, et al. Glanders in a military research microbiologist. N Engl J Med. 2001;345:256-8. 39. Green RN, Tuffnell PG. Laboratory acquired melioidosis. Am J Med. 1968;44:599-605. 40. Schlech WF 3rd, Turchik JB, Westlake RE, Jr., et al. Laboratory-acquired infection with Pseudomonas pseudomallei (melioidosis). N Engl J Med. 1981;305:1133-5. 41. Dance DA. Ecology of Burkholderia pseudomallei and the interactions between environmental Burkholderia spp. and human-animal hosts. Acta Trop. 2000;74:159-68. 177
Page 1 and 2:
Biosafety in Microbiological and Bi
Page 3 and 4:
SECTION VIII-H: Prion Diseases 299
Page 5 and 6:
Forward Biosafety in Microbiologica
Page 7 and 8:
Editors: L. Casey Chosewood, MD Dir
Page 9 and 10:
Guest Editors: Matthew J. Arduino,
Page 11 and 12:
Charles B. Millard, PhD Lieutenant
Page 13 and 14:
Robert Bull Karen B. Byers Jane Cap
Page 15 and 16:
Thomas L. Miller Douglas M. Moore M
Page 17 and 18:
Robert Yarchoan Uri Yokel Lisa Youn
Page 19 and 20:
Introduction laboratories chose not
Page 21 and 22:
Introduction RISK CRITERIA FOR ESTA
Page 23 and 24:
Introduction BMBL includes an impor
Page 25 and 26:
Section II Biological Risk Assessme
Page 27 and 28:
Biological Risk Assessment informat
Page 29 and 30:
Biological Risk Assessment The NIH
Page 31 and 32:
Biological Risk Assessment effectiv
Page 33 and 34:
Biological Risk Assessment Third, m
Page 35 and 36:
Biological Risk Assessment 14. Oxma
Page 37 and 38:
Principles of Biosafety Safety equi
Page 39 and 40:
Principles of Biosafety Often an in
Page 41 and 42:
Principles of Biosafety Four standa
Page 43 and 44:
Principles of Biosafety 4. Centers
Page 45 and 46:
Laboratory Biosafety Level Criteria
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Section V Vertebrate Animal Biosafe
Page 77 and 78:
Vertebrate Animal Biosafety Level C
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
TABLE 1 SUMMARY OF RECOMMENDED BIOS
Page 121 and 122:
Principles of Laboratory Biosecurit
Page 123 and 124:
Principles of Laboratory Biosecurit
Page 125 and 126: Principles of Laboratory Biosecurit
Page 131 and 132: Occupational Health and Immunoproph
Page 139 and 140: Agent Summary Statements - Bacteria
Page 175: Agent Summary Statements - Bacteria
Page 185 and 186: • Section VIII-B: Fungal Agents A
Page 187 and 188: Agent Summary Statements - Fungal A
Page 197 and 198: • Section VIII-C: Parasitic Agent
Page 199 and 200: Agent Summary Statements - Parasiti
Page 209 and 210: • Section VIII-D: Rickettsial Age
Page 211 and 212: Agent Summary Statements - Ricketts
Page 213 and 214: Agent Summary Statements - Ricketts
Page 215 and 216: • Section VIII-E: Viral Agents Ag
Page 217 and 218: Agent Summary Statements - Viral Ag
Page 227 and 228:
Agent Summary Statements - Viral Ag
Page 229 and 230:
Page 231 and 232:
Page 233 and 234:
Page 235 and 236:
Page 237 and 238:
Page 239 and 240:
Page 241 and 242:
Page 243 and 244:
Page 245 and 246:
Agent Summary Statements - Arboviru
Page 247 and 248:
Page 249 and 250:
Page 251 and 252:
Page 253 and 254:
Page 255 and 256:
Page 257 and 258:
Page 259 and 260:
Page 261 and 262:
Page 263 and 264:
Page 265 and 266:
Page 267 and 268:
Page 269 and 270:
Page 271 and 272:
Page 273 and 274:
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
Page 281 and 282:
Page 283 and 284:
Page 285 and 286:
• Section VIII-G: Toxin Agents Se
Page 287 and 288:
Agent Summary Statements - Toxins i
Page 289 and 290:
Agent Summary Statements - Toxins A
Page 291 and 292:
Agent Summary Statements - Toxins L
Page 293 and 294:
Agent Summary Statements - Toxins e
Page 295 and 296:
Agent Summary Statements - Toxins o
Page 297 and 298:
Agent Summary Statements - Toxins t
Page 299 and 300:
• Section VIII-H: Prion Diseases
Page 301 and 302:
Agent Summary Statement - Prion Dis
Page 303 and 304:
Page 305 and 306:
Page 307 and 308:
Appendix A Proper maintenance of ca
Page 309 and 310:
Appendix A declined. However, in ma
Page 311 and 312:
Appendix A It is possible to exhaus
Page 313 and 314:
Appendix A 4. The Class II, Type A2
Page 315 and 316:
Appendix A prohibited. Furthermore,
Page 317 and 318:
Appendix A plastic wrappers, pipett
Page 319 and 320:
Appendix A touch-plate microburners
Page 321 and 322:
Appendix A SECTION VI FACILITY AND
Page 323 and 324:
Appendix A Development of Containme
Page 325 and 326:
Appendix A C. Airflow Smoke Pattern
Page 327 and 328:
Appendix A TABLES Table 1. Selectio
Page 329 and 330:
Appendix A Table 3. Field Performan
Page 331 and 332:
Appendix A FIGURES Figure 1. HEPA f
Page 333 and 334:
Appendix A Figure 3. The Class II,
Page 335 and 336:
Appendix A Figure 5B. The Class II,
Page 337 and 338:
Appendix A Figure 8. The Class III
Page 339 and 340:
Appendix A Figure 9B. The vertical
Page 341 and 342:
Appendix A Figure 11. A typical lay
Page 343 and 344:
Appendix A REFERENCES 1. Centers fo
Page 345 and 346:
Appendix B Decontamination and Disi
Page 347 and 348:
Appendix B surfaces are contaminate
Page 349 and 350:
Appendix B TABLE 1 DESCENDING ORDER
Page 351 and 352:
Appendix B dioxide gas exits the ge
Page 353 and 354:
Appendix B d The effectiveness of a
Page 355 and 356:
Appendix C Transportation of Infect
Page 357 and 358:
Appendix C 1600 Clifton Road, N.E.,
Page 359 and 360:
Appendix C disease in humans or in
Page 361 and 362:
Appendix C Biological specimen, Cat
Page 363 and 364:
Appendix D Agriculture Pathogen Bio
Page 365 and 366:
Appendix D simultaneous opening of
Page 367 and 368:
Appendix D 14. Pathological inciner
Page 369 and 370:
Appendix D Wastes and other materia
Page 371 and 372:
Appendix D Camelpox virus b a, b, c
Page 373 and 374:
Appendix D SPECIAL ISSUES The impor
Page 375 and 376:
Appendix D required by the USDA and
Page 377 and 378:
Appendix D depression, anorexia, an
Page 379 and 380:
Appendix D laboratory with enhancem
Page 381 and 382:
Appendix D five day period of conta
Page 383 and 384:
Appendix D slaughterhouses or indus
Page 385 and 386:
Appendix D virus does not cause any
Page 387 and 388:
Appendix D NDV is classified in the
Page 389 and 390:
Appendix D movement permit is requi
Page 391 and 392:
Appendix D Spring Viremia of Carp V
Page 393 and 394:
Appendix D REFERENCES 1. Hess WR. A
Page 395 and 396:
Appendix D 37. Alexander DJ. Newcas
Page 397 and 398:
Appendix E Arthropod Containment Gu
Page 399 and 400:
Appendix F Select Agents and Toxins
Page 401 and 402:
Appendix G IPM issues and requireme
Page 403 and 404:
Appendix H Working with Human, NHP
Page 405 and 406:
Appendix I Guidelines for Work with
Page 407 and 408:
decontaminated periodically, for ex
Page 409 and 410:
0.25N, and/or sodium hypochlorite (
Page 411 and 412:
k Irradiation causes a dose-depende
Page 413 and 414:
7. Morin R, Kozlovac J. Biological
Page 415 and 416:
Appendix J NIH Oversight of Researc
Page 417 and 418:
Appendix K Resources for Informatio
Page 419 and 420:
Appendix K E-mail: http://www2.gsu.
Page 421 and 422:
Appendix K and http://www.who.int/c
Page 423 and 424:
Appendix L HEPA High Efficiency Par
show all

credits bmbl December 7 '06.doc - Central Michigan University

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?